Healthcare

Starpharma Holdings Limited develops dendrimer-based biotechnology with an emphasis on targeted cancer therapies and drug-delivery applicationsStarpharma Holdings Limited (ASX:SPL) has been progressing its DEP oncology pipeline while reporting changes in funding, partnership activity and research priorities during FY26 and the September quarter.

Telix Pharmaceuticals Limited develops and commercialises diagnostic and therapeutic radiopharmaceuticals for medical imaging and cancer treatment research. Telix Pharmaceuticals Limited (ASX:TLX) reported further imaging-product revenue during the September quarter alongside clinical, regulatory and corporate developments.

CSL Limited develops, manufactures and distributes biopharmaceutical products spanning plasma-derived therapies, vaccines and other specialised medicines. CSL Limited (ASX:CSL) reported a different picture across underlying earnings, reported profit and operating cash flow in its FY26 results, with transformation initiatives continuing across the business.

PolyNovo Limited develops and commercialises medical devices based on its NovoSorb technology for burns and complex wound management. PolyNovo Limited (ASX:PNV) reported growth in its commercial product business in FY26 while pursuing manufacturing, clinical evidence and market-access initiatives.

Sonic Healthcare Limited provides medical diagnostic services, including pathology and laboratory medicine, across its international operations. Sonic Healthcare Limited (ASX:SHL) reported revenue and earnings growth in FY26, with the result reflecting service activity, operating leverage and business integration during the year.

Australian Clinical Labs Limited provides diagnostic pathology services to doctors, hospitals, patients and other clients across Australia. Its business links sample collection with laboratory testing and reporting, placing operational efficiency and clinical service quality at the centre of its activities.

Imricor Medical Systems, Inc. develops devices and systems intended to enable cardiac interventions using magnetic resonance imaging. During 2026, the company reported US regulatory clearances and an initial commercial hospital customer, placing product availability and clinical implementation in focus.